Patients with hematologic malignancies (HMs) struggle with immense physical and
psychological symptom burden, which negatively affect their quality of life (QOL) throughout …

Hematologic malignancies are a heterogeneous group of diseases with unique illness
trajectories, treatment paradigms, and potential for curability, which affect patients' palliative …

Palliative care is a multidisciplinary approach to symptom management, psychosocial
support, and assistance in treatment decision-making for patients with serious illness and …

Specialist palliative care provides additional support to facilitate living well with a serious
illness, like cancer, even while pursuing disease-directed therapy. For patients with …

Hematologic malignancies are heterogeneous and have unpredictable illness trajectories.
Intensive therapies, such as hematopoietic stem cell transplant (HSCT) and chimeric antigen …

Patients with hematologic malignancies and other serious blood disorders often have
significant symptom burden and unmet supportive/palliative care needs during their disease …

Hematologic malignancies differ in several important ways from solid organ cancers, and
warrant a unique approach to palliative care (PC) integration. As PC has moved upstream …

Palliative care is state-of-the-art, specialized medical care for patients who are facing a
serious illness. It can be provided alongside even curative-intent cancer care and is …

The provision of specialty palliative care alongside oncology care is now recommended by
the American Society of Clinical Oncology (ASCO) on the basis of multiple randomized trials …

Patients with hematologic malignancies (HM) nowadays rarely receive palliative or hospice
care, and studies on potential effects of integrated palliative care are rare. This narrative …